Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Type 2 diabetes mellitus is a chronic metabolic disorder characterized by progressive
deterioration in the function of the pancreatic beta-cells, which are the cells that produce
and secrete insulin (the hormone primarily responsible for the handling of glucose in the
body). The investigators propose a randomized controlled trial to determine whether combining
basal insulin with a new medication called exenatide is a therapeutic strategy that can
preserve beta-cell function early in the course of type 2 diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Mount Sinai Hospital, Canada
Collaborators:
Canadian Institutes of Health Research (CIHR) University of Toronto